Premium
XXXVI. The persistent biometric problems of the UGDP study
Author(s) -
Feinstein Alvan R.
Publication year - 1976
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1976194472
Subject(s) - scrutiny , warrant , legislation , clinical trial , political science , law , medicine , family medicine , business , finance
As a medical cause célébre of our era, the therapeutic trial conducted as the University Group Diabetes Program (UGDP) has been a fertile source of educational material. The study itself and the controversies it has engendered have produced issues that are now being avidly discussed not only for their clinical and statistical consequences, but also for their impact in such domains as law, ethics, health policy, legislation, press relations, and medical statesmanship. Although many editors and readers may be tired of hearing about the UGDP, it continues to warrant thorough attention and scrutiny because its wide‐ranging implications extend far beyond the immediate topic of pharmaceutical treatment for patients with diabetes mellitus.